Lecap Asset Management Ltd. Boosts Position in Illumina, Inc. (NASDAQ:ILMN)

Lecap Asset Management Ltd. boosted its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 121.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,208 shares of the life sciences company's stock after purchasing an additional 25,910 shares during the period. Illumina comprises 0.9% of Lecap Asset Management Ltd.'s investment portfolio, making the stock its 13th largest position. Lecap Asset Management Ltd.'s holdings in Illumina were worth $3,745,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of ILMN. Private Advisor Group LLC increased its stake in Illumina by 2.1% in the 4th quarter. Private Advisor Group LLC now owns 11,293 shares of the life sciences company's stock worth $1,509,000 after purchasing an additional 234 shares during the period. Concurrent Investment Advisors LLC increased its stake in Illumina by 8.2% in the 4th quarter. Concurrent Investment Advisors LLC now owns 1,731 shares of the life sciences company's stock worth $231,000 after purchasing an additional 131 shares during the period. First Horizon Advisors Inc. increased its stake in Illumina by 73.5% in the 4th quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company's stock worth $59,000 after purchasing an additional 186 shares during the period. Howard Capital Management Inc. increased its stake in Illumina by 3.0% in the 4th quarter. Howard Capital Management Inc. now owns 5,380 shares of the life sciences company's stock worth $719,000 after purchasing an additional 155 shares during the period. Finally, Y Intercept Hong Kong Ltd increased its stake in Illumina by 506.0% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 19,300 shares of the life sciences company's stock worth $2,579,000 after purchasing an additional 16,115 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ILMN shares. Stephens reissued an "overweight" rating and set a $105.00 target price on shares of Illumina in a research note on Tuesday, May 20th. Barclays reissued an "underweight" rating and set a $85.00 target price (up from $77.00) on shares of Illumina in a research note on Tuesday. Morgan Stanley reduced their target price on Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research note on Monday, May 12th. Royal Bank Of Canada reduced their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 8th. Finally, Canaccord Genuity Group boosted their target price on Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a research note on Wednesday, June 11th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $127.39.

Illumina Stock Performance

Shares of NASDAQ:ILMN traded up $0.63 during midday trading on Friday, reaching $94.79. 3,837,289 shares of the company's stock traded hands, compared to its average volume of 2,148,341. The company has a market cap of $15.01 billion, a price-to-earnings ratio of -15.62, a P/E/G ratio of 1.85 and a beta of 1.32. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.48 and a current ratio of 1.86. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The stock has a 50 day moving average of $82.69 and a 200 day moving average of $99.32.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The company's quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.98 earnings per share. As a group, equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Activity at Illumina

In other news, CFO Ankur Dhingra acquired 6,100 shares of Illumina stock in a transaction that occurred on Monday, May 12th. The stock was bought at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the transaction, the chief financial officer now owns 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.60% of the stock is owned by company insiders.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.